Cure could Perceive Mesothelioma and Pancreatic Cancer:
U.S.
scientists have found specific changes in the blood of patients with two fatal
cancers that would enable doctors to diagnose these diseases before.
With
a new imaging technology in Soma logic Inc, a research team of the company said
that it could detect early signs of pancreatic cancer and a type of lung tumor
called Mesothelioma in patients diagnosed yet untreated.
"These Pancretic Cancers are detected at an advanced stage when the possibility of cure is
minimal," said Rachel Ostroff, director of clinical research and Soma
logic Inc responsible for presenting the results at a meeting of the American
Association for Cancer Research.
"The
detection of these aggressive cancers at an earlier stage would identify
patients to offer a treatment that improves survival and quality of life,"
he said.
Pancreatic
cancer is relatively rare, but it is the fourth leading cause of cancer death
in the United States. Mesothelioma caused by asbestos, kills between 15,000 and
20,000 people per year worldwide.
This
last one is characterized by affecting the Mesothelioma, a membrane lining
several body cavities: the peritoneal (abdominal cavity lining), the tunica virginals,
and pericardium (lining of the heart), but the vast majority of cases are
originated in the pleura (membrane that lines the chest cavity and lungs).
People
exposed to asbestos for a long time or exposed to high levels of asbestos have
a higher risk of developing malignant Mesothelioma, but even those exposed for
a short time can develop this disease, which tends to appear a long period of
time after the exposure: at least 15 years (usually 20 to 40 years) after. This
disease is usually diagnosed between 50 and 70 years, men being more likely to
contract the disease (they are more likely to be exposed to asbestos).
The
new technology detects the disease by analyzing proteins in a drop of blood. Soma
logic tests using the genetic material fragments that attach to proteins. Soma
logic refined a technology that achieves these molecules join specific
proteins.
The
team analyzed blood samples of patients with both cancer and control groups
(with diseases that produce symptoms similar to those of cancers such as lung
fibrosis or pancreatitis).
The
researchers used computer models to identify significant biological
differences, or biomarkers that distinguished blood samples of patients with
cancer of the control group.
For
both cancers, the researchers found biomarkers of high accuracy and specificity
for detecting each type of cancer. Now, it is confirmed by other studies to
ensure playback on diagnostic tests.
"It's
very easy to discover biomarkers, validate them is, on the other hand,
difficult" said Ostroff, who announced that the team will analyze several
factors that could generate false positives, as the age of a sample in a rack
before submitting it to the test.
No comments:
Post a Comment